Pediatric Neuroblastoma Treatment Market by Treatment Type (Immunotherapy, Chemotherapy, and Radiation Therapy), Risk Group (Low Risk, Intermediate Risk and High Risk), End User (Hospitals and Cancer Specialty Centers) - Analysis & Forecast 2019-2030.

Report ID : 225  |  Published Date : Feb 2020  |  Pages : 175  |  Region : Global  |  Report Code : PH-15





Pediatric Neuroblastoma Treatment Market Overview and Introduction

Neuroblastoma is the most common type of cancer found in infants & young children and accounts for up to 10% of the total pediatric cancer. It is caused due to embryonal malignancy of the sympathetic nervous system which arises from the neuroblasts. Neuroblastoma is most often found in the nerve tissues of adrenal glands. It may also develop in the abdominal part of the body including chest, neck or near spinal cord. Neuroblastoma rarely occurs after the age of around 10 years.

The global pediatric neuroblastoma treatment market is mainly driven by increasing prevalence of neuroblastoma in children, rising awareness about available treatments and improvements in the healthcare infrastructure. Moreover, rising R&D activities also play a pivotal role in contributing to market growth globally. However, high cost of this therapy associated with the treatment is likely to restrain market growth to a certain extent.

The global pediatric neuroblastoma treatment market can be segmented into treatment type, risk group, end users, and regions.

Pediatric Neuroblastoma Treatment Market By Treatment Type

Based on treatment type, the market is segmented into immunotherapy, chemotherapy, radiation therapy and others. The chemotherapy segment is expected to dominate the pediatric neuroblastoma treatment market during the forecast period. Chemotherapy is the treatment of choice owing to its effectiveness in slowing down the growth or spread of the disease. Furthermore, use of chemotherapy along with other treatments such as radiation therapy or surgery may give the optimum results. These overall factors are expected to boost the growth of this segment.

Pediatric Neuroblastoma Treatment Market by Risk Group

Based on risk group, the market can be segmented into low risk, intermediate risk and high risk. The high risk segment is expected to dominate the pediatric neuroblastoma treatment market during the forecast period owing to more intensive treatments such as chemotherapy, surgery, radiation, stem cell transplant, immunotherapy etc. needed in high risk group in order to have best chance of being cured.

Pediatric Neuroblastoma Treatment Market by End User

Based on end user, the market can be segmented into hospitals, cancer specialty centers and others. The hospitals segment is expected to dominate the pediatric neuroblastoma treatment market followed by cancer specialty centers during the forecast period. Frequent visits of patients to hospitals for diagnosis and treatment of cancer can be considered as one of the major factor responsible for the growth of the segment.

Pediatric Neuroblastoma Treatment Market by Region

Based on region, the global pediatric neuroblastoma treatment market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the pediatric neuroblastoma treatment market, followed by Asia Pacific. The growth in North America can be attributed to the high number of ongoing R&D activities, advanced health care infrastructure and better reimbursement plans.

Pediatric Neuroblastoma Treatment Market Prominent Players

Some of the prominent players in the pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG., EUSA Pharma, CELLECTAR BIOSCIENCES, INC., Y-mAbs Therapeutics, Inc., Pfizer Inc., MacroGenics, Inc., Baxter, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Ltd. among others.

Table of Contents

  1. INTRODUCTION
    1. Market Definition
    2. Market Classification
    3. Geographic Scope
    4. Years Considered for the Study: Historical Years – 2016 & 2017; Base Year – 2018; Forecast Years – 2019 to 2030
    5. Currency Used
  2. RESEARCH METHODOLOGY
    1. Research Framework
    2. Data Collection Technique
    3. Data Sources
      1. Secondary Sources
      2. Primary Sources
    4. Market Estimation Methodology
      1. Bottom Up Approach
      2. Top Down Approach
    5. Data Validation and Triangulation
      1. Market Forecast Model
      2. Limitations/Assumptions of the Study
  3. ABSTRACT OF THE STUDY
  4. MARKET DYNAMICS ASSESSMENT
    1. Overview
    2. Drivers
    3. Barriers/Challenges
    4. Opportunities
  5. UNIQUE SELLING PROPOSITIONS (USPs)
    1. Pipeline Assessment
  6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
    1. Immunotherapy
    2. Chemotherapy
    3. Radiation Therapy
    4. Others
  7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY RISK GROUP
    1. Low Risk
    2. Intermediate Risk
    3. High Risk
  8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY END USER
    1. Hospitals
    2. Cancer Specialty Centers
    3. Others
  9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Pediatric Neuroblastoma Treatment Market
      1. North America Pediatric Neuroblastoma Treatment Market, By Country
        1.  US
        2.  Canada
      2. North America Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Treatment Type
      3. North America Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Risk Group
      4. North America Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By End User
    2. Europe Pediatric Neuroblastoma Treatment Market
      1. Europe Pediatric Neuroblastoma Treatment Market, By Country/Region
        1. Germany
        2. UK
        3. France
        4. Rest of Europe (ROE)
      2. Europe Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Treatment Type
      3. North America Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Risk Group
      4. Europe Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By End User
    3. Asia Pacific Pediatric Neuroblastoma Treatment Market
      1. Asia Pacific Pediatric Neuroblastoma Treatment Market, By Country/Region
        1. China
        2. Japan
        3. India
        4. Rest of Asia Pacific (RoAPAC)
      2. Asia Pacific Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Treatment Type
      3. North America Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Risk Group
      4. Asia Pacific Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By End User
    4. Rest of the World (ROW) Pediatric Neuroblastoma Treatment  Market
      1. Rest of the World Pediatric Neuroblastoma Treatment Market, By Country/ Region
        1.  Latin America
        2.  Middle East & Africa
      2. Rest of the World Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Treatment Type
      3. North America Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By Risk Group
      4. Rest of the World Pediatric Neuroblastoma Treatment Market Analysis & Forecast, By End User
  10. COMPETETIVE LANDSCAPE
    1. Market Share Analysis (2018)
    2. Key Strategies Assessment
      1. New Product Launches
      2. Merger & Acquisitions
      3. Agreements, Collaborations, & Partnerships
      4. Expansions
      5. Other Strategies
  11. COMPANY PROFILES                (Business Overview, Products Offered, Financial Performance*, Recent Developments)
    1. United Therapeutics Corporation
    2. APEIRON Biologics AG.
    3. EUSA Pharma
    4. CELLECTAR BIOSCIENCES, INC.
    5. Y-mAbs Therapeutics, Inc.
    6. Pfizer Inc.
    7. MacroGenics, Inc.
    8. Baxter
    9. Bristol-Myers Squibb Company
    10. Teva Pharmaceutical Industries Ltd.                       *Financial details might not be captured in case of privately-held companies or for companies that do not report this information in public domain